Vera Therapeutics, Inc. (NASDAQ:VERA) Insider Joanne Curley Sells 1,545 Shares

Vera Therapeutics, Inc. (NASDAQ:VERAGet Rating) insider Joanne Curley sold 1,545 shares of the stock in a transaction on Wednesday, June 22nd. The shares were sold at an average price of $15.01, for a total value of $23,190.45. Following the completion of the transaction, the insider now directly owns 23,688 shares of the company’s stock, valued at $355,556.88. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Joanne Curley also recently made the following trade(s):

  • On Friday, June 17th, Joanne Curley sold 5,887 shares of Vera Therapeutics stock. The shares were sold at an average price of $15.04, for a total value of $88,540.48.

Vera Therapeutics stock traded down $0.60 during midday trading on Thursday, reaching $13.62. 43,567 shares of the stock traded hands, compared to its average volume of 100,045. The company has a 50-day simple moving average of $16.75 and a two-hundred day simple moving average of $20.24. Vera Therapeutics, Inc. has a 12-month low of $12.28 and a 12-month high of $37.11. The firm has a market cap of $368.63 million and a PE ratio of -6.22. The company has a current ratio of 7.90, a quick ratio of 7.90 and a debt-to-equity ratio of 0.04.

Vera Therapeutics (NASDAQ:VERAGet Rating) last announced its earnings results on Monday, May 16th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.04). Equities research analysts anticipate that Vera Therapeutics, Inc. will post -3.04 earnings per share for the current year.

A number of analysts have issued reports on VERA shares. HC Wainwright started coverage on Vera Therapeutics in a research note on Monday, May 2nd. They issued a “buy” rating and a $35.00 target price for the company. Wedbush initiated coverage on Vera Therapeutics in a research report on Monday, April 18th. They set an “outperform” rating and a $32.00 price objective for the company. Finally, Lifesci Capital reissued an “outperform” rating on shares of Vera Therapeutics in a research report on Monday, March 28th.

A number of institutional investors have recently made changes to their positions in VERA. UBS Group AG purchased a new position in shares of Vera Therapeutics in the 1st quarter valued at about $47,000. American International Group Inc. boosted its stake in shares of Vera Therapeutics by 29.2% in the 1st quarter. American International Group Inc. now owns 6,794 shares of the company’s stock valued at $160,000 after buying an additional 1,535 shares during the period. New York State Common Retirement Fund boosted its stake in shares of Vera Therapeutics by 445.8% in the 4th quarter. New York State Common Retirement Fund now owns 6,549 shares of the company’s stock valued at $175,000 after buying an additional 5,349 shares during the period. MetLife Investment Management LLC purchased a new position in shares of Vera Therapeutics in the 1st quarter valued at about $209,000. Finally, Rhumbline Advisers purchased a new position in shares of Vera Therapeutics in the 1st quarter valued at about $244,000. Institutional investors own 78.57% of the company’s stock.

About Vera Therapeutics (Get Rating)

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy.

Featured Stories

Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.